Regarding the clinical manifestations of the participants at the time of enrollment to the study, the most common manifestations were arthritis and arthralgia, which were present in all the patients in the baricitinib and TNF Inhibitors groups, and 99% and 98% of the patients in the cDMARDs group respectively. Here, TNF is linked to arthritic joint disease.